Bevacizumab-vikg Wet AMD Trial Raises Eyebrows Bevacizumab-vikg Wet AMD Trial Raises Eyebrows
An ' apples-to-oranges ' comparison of bevacizumab-vikg to ranibizumab is troubling some experts who would like to see the drug approved.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Susvimo (ranibizumab)
Title: Susvimo (ranibizumab)Category: MedicationsCreated: 10/27/2021 12:00:00 AMLast Editorial Review: 10/27/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - October 27, 2021 Category: Opthalmology Source Type: news
Susvimo (Ranibizumab Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 26, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Drugs for Wet AMD, Macular Edema Due to Uveitis FDA Approves Drugs for Wet AMD, Macular Edema Due to Uveitis
Wet AMD gets Susvimo, an intravitreal ranibizumab injection, and macular edema gets Xipere, a triamcinolone acetonide injectable suspension.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2021 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
Genentech wins FDA approval for unique refillable treatment targeting blinding eye disease
The FDA approval comes as Genentech and parent Roche face generic competition for Lucentis and other companies pursue longer-acting drugs for wet AMD patients. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 23, 2021 Category: American Health Authors: Ron Leuty Source Type: news
Genentech wins FDA approval for unique refillable treatment targeting blinding eye disease
The FDA approval comes as Genentech and parent Roche face generic competition for Lucentis and other companies pursue longer-acting drugs for wet AMD patients. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 22, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news
FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizumab, is the f...
Source: Roche Media News - October 22, 2021 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizumab, is the f...
Source: Roche Investor Update - October 22, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Susvimo (ranibizumab) for the Treatment of Wet Age-Related Macular Degeneration (AMD)
South San Francisco, CA -- October 22, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 22, 2021 Category: Drugs & Pharmacology Source Type: news
Black Patients Benefit Less From Ranibizumab Black Patients Benefit Less From Ranibizumab
Findings raise questions that highlight the lack of data on ethnicity in clinical trials of retina treatments.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 9, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ophthalmologist Pleads Guilty to Using Misbranded Medication
FDA OCI, James Heroman, Charlotte NC, M.D., guilty plea, misbranded medication, opthalmologist, Carolina Retina, Vitreous Consultants, CRVC, unapproved, foreign, cheap, macular degeneration, Lucentis, Medicare, bill, price difference, profit, False Claims Act, violations, health care fraud (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - October 7, 2021 Category: Medical Law Authors: DOJ Source Type: news
Byooviz (Ranibizumab-nuna Injection, for Intravitreal Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 29, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Ranibizumab Biosimilar FDA Approves Ranibizumab Biosimilar
Byooviz has the potential to be less expensive than Lucentis, the reference product.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2021 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news
FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news
